222 Photos and videos
Jun 10
The NULISA™ DBS Extraction Kit streamlines protein extraction from DBS and DPS with a standardized, scalable workflow. Learn how it supports sensitive proteomic analysis and enables longitudinal, decentralized, and large-scale studies.
🔗 Download: na2.hubs.ly/H060tNX0
1
17
Jun 8
Join us at #FOCIS2026 this week to explore how ultra-sensitive proteomics is advancing immunology research.
Don't miss presentations from Dr. Holden Maecker (Stanford) and Dr. Hayeun Ji (Alamar). Visit Booth 15 to connect with our team.
Learn more: na2.hubs.ly/H060FBX0
39
Jun 5
Unlock high-quality proteomic data from dried blood and plasma spots.
The NULISA™ DBS Extraction Kit enables standardized protein recovery from DBS and DPS samples collected across leading microsampling platforms.
Learn more: na2.hubs.ly/H05Y_nl0
24
Jun 3
Join us at the 2026 FOCIS Annual Meeting and discover how ultra-sensitive NULISA™ proteomics is helping researchers unlock deeper insights into immune biology.
Learn more: na2.hubs.ly/H05WTKW0
23
Jun 2
🩸Meet the NULISA™ DBS Extraction Kit
Turn DBS/DPS microsamples into high-quality, analysis-ready specimens with a standardized, high-throughput workflow—enabling remote and longitudinal study designs.
Learn more: na2.hubs.ly/H05T1Vn0
Read release: na2.hubs.ly/H05T4Gm0
53
Jun 1
Multiple sclerosis is a complex disease that demands earlier detection and more precise monitoring. We're proud to support MS researchers with ultra-sensitive proteomics tools that help uncover critical biomarkers.
#WorldMSDay #Proteomics
35
May 22
Join Alamar Biosciences at the 7th World Parkinson's Disease Congress as the global Parkinson’s disease community comes together to explore the latest breakthroughs in PD research, biomarker discovery, and emerging therapeutics.
Learn more: na2.hubs.ly/H05J0lD0
24
May 19
Don’t miss the 2026 Summit Advancing TDP-43 Biomarkers this Thursday. Virtual registration closes soon.
Join leaders in neurodegeneration research as they discuss the latest advances in TDP-43 biomarker discovery and ADRD research.
Register virtually: na2.hubs.ly/H05BhT40
29
May 7
Join us live from Amsterdam UMC on May 21 as researchers discuss ultra-sensitive proteomics and biomarker discovery in dementia & MS - with live online access available.
Featuring speakers from AUMC, DZNE, UCL, HKUST & Barcelonaβeta/Lund.
👉 Register: na2.hubs.ly/H05kGNX0
45
Apr 30
📍 We’ll be at XXXIV AINI Congress in Rome!
Learn how ultra-sensitive, multiplex proteomics can reveal biomarkers that refine MS phenotyping and biology in our speaker session with Anna Wojdala, PhD (Amsterdam UMC).
👉 na2.hubs.ly/H05cfJj0
43
Apr 29
🧬 International Day of Immunology
Our ultra-sensitive NULISA technologies help researchers measure low-abundance biomarkers and uncover the biology driving disease.
We're proud to support the research advancing the boundaries of immunology.
#InternationalDayofImmunology
38
AlamarBio retweeted
Apr 25
“Under-promise and over deliver. And that has been the philosophy of building this company."
@AlamarBio Founder, Chairman, and CEO Yuling Luo shares the $ALMR journey to listing day. #NasdaqListed
1
3
14
2,987
Apr 27
Happening this week, CSI brings together researchers advancing immunology.
See how NULISA™ enables ultra-sensitive, multiplex protein analysis for low-abundance biomarkers and deeper insights.
Visit our table to learn more.
43
Apr 24
Join our webinar with Labroots featuring Dr. Steve Williams, CSO at Alamar Biosciences, to learn how NULISA™ enables ultra-sensitive, multiplex detection of low-abundance protein biomarkers from small blood samples.
Register now: na2.hubs.ly/H053N8F0
1
74
Apr 22
The past week marked an important milestone for Alamar. Our focus remains the same: powering precision proteomics to enable earlier disease detection. We’re grateful to our community and energized for what’s ahead.
#NasdaqListed $ALMR
2
254
Apr 20
A milestone moment for Alamar.
Grateful to our team, customers, partners, and investors who made this possible.
Listing on @Nasdaq marks a new chapter as we continue advancing ultra‑sensitive, multiplex precision proteomics for earlier disease detection.🚀
#NasdaqListed $ALMR
Apr 17
.@AlamarBio is powering precision proteomics with unrivaled sensitivity and simplicity to enable the earliest detection of disease.
Honored to welcome you to Nasdaq, $ALMR! #NasdaqListed
1
128
Apr 16
🚨 Only two weeks left to apply for the Parkinson’s Disease Grant Program.
Apply by April 30, 2026, for a chance to receive one of 3 awards, including analysis of 86 samples using the NULISAseq™ Neuro 220 Panel.
🔗 Apply now: na2.hubs.ly/H04Vxq_0
62
Apr 15
Join our Spotlight Theater at AACR featuring Adam Grippin, Aaron Kilgallon, and Steve Williams on how NULISA is being applied to uncover low-abundance biomarkers, profile complex tumor and immune biology, and accelerate translational research.
👉 na2.hubs.ly/H04TTGY0
157
Apr 14
We’re onsite in Boston for the 8th Annual NDDS, bringing together leaders across biotech, pharma, and academia to advance neuroimmune therapies.
Join Max Mahoney (Alamar Biosciences) for tomorrow's presentation on the NULISA Platform.
👉 na2.hubs.ly/H04SBVx0
69
Apr 14
Parkinson’s disease affects more than 10 million people globally and often begins long before symptoms appear, making early understanding critical.
We’re committed to earlier detection through ultra-sensitive precision proteomics to help uncover the signals that matter.
1
47